✦ LIBER ✦

Design of Novel, Potent, and Selective Human β-Tryptase Inhibitors Based on α-Keto-[1,2,4]-oxadiazoles.

✍ Scribed by Chang-Sun Lee; Weili Liu; Paul A. Sprengeler; John R. Somoza; James W. Janc; David Sperandio; Jeffrey R. Spencer; Michael J. Green; Mary E. McGrath

Publisher: John Wiley and Sons
Year: 2006
Weight: 12 KB
Volume: 37
Category: Article
ISSN: 0931-7597
DOI: 10.1002/chin.200647143

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.

📜 SIMILAR VOLUMES

Design and Synthesis of Selective Keto-1

Design and Synthesis of Selective Keto-1,2,4-oxadiazole-based Tryptase Inhibitors.

✍ James T. Palmer; Robert M. Rydzewski; Rohan V. Mendonca; David Sperandio; Jeffre 📂 Article 📅 2006 🏛 John Wiley and Sons ⚖ 12 KB

Convergent, Parallel Synthesis of a Seri

Convergent, Parallel Synthesis of a Series of β-Substituted 1,2,4-Oxadiazole Butanoic Acids as Potent and Selective αvβ3 Receptor Antagonist.

✍ Mark L. Boys; et al. et al. 📂 Article 📅 2006 🏛 John Wiley and Sons ⚖ 16 KB 👁 1 views

ChemInform Abstract: Benzo[c]quinolizin-

ChemInform Abstract: Benzo[c]quinolizin-3-ones: A Novel Class of Potent and Selective Nonsteroidal Inhibitors of Human Steroid 5α-Reductase 1.

✍ Antonio Guarna; Fabrizio Machetti; Ernesto G. Occhiato; Dina Scarpi; Alessandra 📂 Article 📅 2001 🏛 John Wiley and Sons ⚖ 33 KB 👁 2 views

p38 MAP Kinase Inhibitors. Part 1. Desig

p38 MAP Kinase Inhibitors. Part 1. Design and Development of a New Class of Potent and Highly Selective Inhibitors Based on 3,4-Dihydropyrido[3,2-d]pyrimidone Scaffold.

✍ Swaminathan R. Natarajan; et al. et al. 📂 Article 📅 2003 🏛 John Wiley and Sons ⚖ 185 KB 👁 2 views

Discovery of 4-Heteroarylbicyclo[2.2.2]o

Discovery of 4-Heteroarylbicyclo[2.2.2]octyltriazoles as Potent and Selective Inhibitors of 11β-HSD1: Novel Therapeutic Agents for the Treatment of Metabolic Syndrome.

✍ Xin Gu; et al. et al. 📂 Article 📅 2006 🏛 John Wiley and Sons ⚖ 15 KB

Preclinical pharmacokinetics and metabol

Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38α inhibitor: identification of an active metabolite in preclinical species and human liver microsomes

✍ Amit S. Kalgutkar; Heather L. Hatch; Frederick Kosea; Hang T. Nguyen; Edna F. Ch 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 406 KB 👁 1 views